Role of interferon gamma release assay in the diagnosis and management of Mycobacterium tuberculosis-associated uveitis: A review

Samra Rahman; Muhammad Irfan; M. A. Rehman Siddiqui

doi:10.1136/bmjophth-2020-000663

Role of interferon gamma release assay in the diagnosis and management of Mycobacterium tuberculosis-associated uveitis: A review

Research output: Contribution to journal › Review article › peer-review

17 Citations (Scopus)

Abstract

Tuberculosis (TB)-associated uveitis is a common cause of infectious uveitis in the developing world. Diagnosis of TB uveitis remains a challenge. The role of interferon gamma release assays (IGRAs) is uncertain. Herein we summarise the available literature on the utility of IGRAs in the diagnosis and management of TB uveitis. We searched PubMed database from 1 August 2010 to 31 July 2020 using the following keywords alone and in combination: â € interferon-gamma release assay', â € QuantiFERON', â € T-SPOT.TB', â € TB uveitis', â € serpiginous like choroiditis', â € tuberculoma', â € TB vasculitis', â € TB panuveitis' and â € ocular tuberculosis'. Data from 58 relevant studies were collated. The review is focused on currently marketed versions of IGRA tests: QuantiFERON-TB Gold In-Tube assay, QuantiFERON-TB Gold Plus assay (QFT-Plus) and T-SPOT.TB. We found limited evidence regarding the diagnostic utility of IGRA in patients with uveitis. No study was identified evaluating the newer QFT test-the QFT-Plus-in patients with uveitis. Similarly, there is lack of data directly comparing QFT-Plus with T-SPOT.TB specifically for the diagnosis of TB uveitis.

Original language	English (US)
Article number	e000663
Journal	BMJ Open Ophthalmology
Volume	6
Issue number	1
DOIs	https://doi.org/10.1136/bmjophth-2020-000663
Publication status	Published - 12 May 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

diagnostic tests/investigation
infection
inflammation

Access to Document

10.1136/bmjophth-2020-000663

Cite this

@article{97f126aa4f0045d28320244ca693f2de,

title = "Role of interferon gamma release assay in the diagnosis and management of Mycobacterium tuberculosis-associated uveitis: A review",

abstract = "Tuberculosis (TB)-associated uveitis is a common cause of infectious uveitis in the developing world. Diagnosis of TB uveitis remains a challenge. The role of interferon gamma release assays (IGRAs) is uncertain. Herein we summarise the available literature on the utility of IGRAs in the diagnosis and management of TB uveitis. We searched PubMed database from 1 August 2010 to 31 July 2020 using the following keywords alone and in combination: {\^a} € interferon-gamma release assay', {\^a} € QuantiFERON', {\^a} € T-SPOT.TB', {\^a} € TB uveitis', {\^a} € serpiginous like choroiditis', {\^a} € tuberculoma', {\^a} € TB vasculitis', {\^a} € TB panuveitis' and {\^a} € ocular tuberculosis'. Data from 58 relevant studies were collated. The review is focused on currently marketed versions of IGRA tests: QuantiFERON-TB Gold In-Tube assay, QuantiFERON-TB Gold Plus assay (QFT-Plus) and T-SPOT.TB. We found limited evidence regarding the diagnostic utility of IGRA in patients with uveitis. No study was identified evaluating the newer QFT test-the QFT-Plus-in patients with uveitis. Similarly, there is lack of data directly comparing QFT-Plus with T-SPOT.TB specifically for the diagnosis of TB uveitis.",

keywords = "diagnostic tests/investigation, infection, inflammation",

author = "Samra Rahman and Muhammad Irfan and \{Rehman Siddiqui\}, \{M. A.\}",

note = "Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2021",

month = may,

day = "12",

doi = "10.1136/bmjophth-2020-000663",

language = "English (US)",

volume = "6",

journal = "BMJ Open Ophthalmology",

issn = "2397-3269",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Role of interferon gamma release assay in the diagnosis and management of Mycobacterium tuberculosis-associated uveitis

T2 - A review

AU - Rahman, Samra

AU - Irfan, Muhammad

AU - Rehman Siddiqui, M. A.

N1 - Publisher Copyright: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2021/5/12

Y1 - 2021/5/12

N2 - Tuberculosis (TB)-associated uveitis is a common cause of infectious uveitis in the developing world. Diagnosis of TB uveitis remains a challenge. The role of interferon gamma release assays (IGRAs) is uncertain. Herein we summarise the available literature on the utility of IGRAs in the diagnosis and management of TB uveitis. We searched PubMed database from 1 August 2010 to 31 July 2020 using the following keywords alone and in combination: â € interferon-gamma release assay', â € QuantiFERON', â € T-SPOT.TB', â € TB uveitis', â € serpiginous like choroiditis', â € tuberculoma', â € TB vasculitis', â € TB panuveitis' and â € ocular tuberculosis'. Data from 58 relevant studies were collated. The review is focused on currently marketed versions of IGRA tests: QuantiFERON-TB Gold In-Tube assay, QuantiFERON-TB Gold Plus assay (QFT-Plus) and T-SPOT.TB. We found limited evidence regarding the diagnostic utility of IGRA in patients with uveitis. No study was identified evaluating the newer QFT test-the QFT-Plus-in patients with uveitis. Similarly, there is lack of data directly comparing QFT-Plus with T-SPOT.TB specifically for the diagnosis of TB uveitis.

AB - Tuberculosis (TB)-associated uveitis is a common cause of infectious uveitis in the developing world. Diagnosis of TB uveitis remains a challenge. The role of interferon gamma release assays (IGRAs) is uncertain. Herein we summarise the available literature on the utility of IGRAs in the diagnosis and management of TB uveitis. We searched PubMed database from 1 August 2010 to 31 July 2020 using the following keywords alone and in combination: â € interferon-gamma release assay', â € QuantiFERON', â € T-SPOT.TB', â € TB uveitis', â € serpiginous like choroiditis', â € tuberculoma', â € TB vasculitis', â € TB panuveitis' and â € ocular tuberculosis'. Data from 58 relevant studies were collated. The review is focused on currently marketed versions of IGRA tests: QuantiFERON-TB Gold In-Tube assay, QuantiFERON-TB Gold Plus assay (QFT-Plus) and T-SPOT.TB. We found limited evidence regarding the diagnostic utility of IGRA in patients with uveitis. No study was identified evaluating the newer QFT test-the QFT-Plus-in patients with uveitis. Similarly, there is lack of data directly comparing QFT-Plus with T-SPOT.TB specifically for the diagnosis of TB uveitis.

KW - diagnostic tests/investigation

KW - infection

KW - inflammation

UR - https://www.scopus.com/pages/publications/85105853783

U2 - 10.1136/bmjophth-2020-000663

DO - 10.1136/bmjophth-2020-000663

M3 - Review article

AN - SCOPUS:85105853783

SN - 2397-3269

VL - 6

JO - BMJ Open Ophthalmology

JF - BMJ Open Ophthalmology

IS - 1

M1 - e000663

ER -

Role of interferon gamma release assay in the diagnosis and management of Mycobacterium tuberculosis-associated uveitis: A review

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this